Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-
associated virus (AAV) vector-based gene therapies. Mild to severe adverse events …

Recent advances in ocular gene and cellular therapy rely on precisely controlled subretinal
delivery. Due to its inherent limitations, manual delivery can lead to iatrogenic damage to the …

Recent advances in optogenetics hold promise for vision restoration in degenerative eye
diseases. Optogenetics refers to techniques that use light to control the cellular activity of …

Recombinant adeno-associated virus (rAAV) vectors are currently the only proven vehicles
for treating ophthalmological diseases through gene therapy. A wide range of gene therapy …

The present review discusses emerging gene therapy options which could foster new, more
durable nAMD and nnAMD therapeutics. These options will need refinement with regards to …

The purpose of this paper is to review human leukocyte antigen G (HLA-G) in the eye, its
role in immune tolerance, and the potential therapeutic use of AAV gene transfer and …

Glaucoma is a group of optic neuropathies featured by degeneration of retinal ganglion cells
and loss of their axons in the optic nerve. The only currently approved therapies focus on …

Equine recurrent uveitis (ERU) is a spontaneous, painful, and vision threatening disease
affecting up to 25% of equine populations worldwide. Current treatments of ERU are non …

Objectives: AAV vectors are widely used in gene therapy, but the prevalence of neutralizing
antibodies raised against AAV serotypes in the course of a natural infection, as well as …

The underlying immune state of inherited retinal degenerations (IRDs) and retinitis
pigmentosa (RP) has been an emerging area of interest, where in the consequences have …